BACKGROUND Despite widespread use of adrenergic agents in the management of
asthma for many decades, doubts have emerged concerning the safety and efficacy of long …

The long-acting b-agonists (LABAs) were introduced as asthma treatments in the 1990s, and
their use was shown to result in improved lung function and quality of life. Concerns about …

Role of long-acting β2-adrenergic agonists in asthma managem... : Current Opinion in
Pulmonary Medicine Role of long-acting β2-adrenergic agonists in asthma management based …

Abstract β 2-Adrenoceptors are widely, almost ubiquitously, expressed. Activation of these
receptors on bronchial smooth muscle by short-and long-acting β 2-adrenoceptor agonists …

An epidemic of asthma fatalities in the 1970s prompted a series of case-control studies
which indicated that short acting β-agonists increased the risk of death. Subsequent …

For over 30 years, P-adrenoceptor agonists have been used routinely in the treatment of
bronchial asthma. The therapeutic use of these compounds is derived from their ability to …

The FDA and Safe Use of Long-Acting Beta-Agonists in the Treatment of Asthma | New England
Journal of Medicine Skip to main content The New England Journal of Medicine homepage …

After the discovery of formoterol and salmeterol, new candidates for long-acting β2-
adrenoceptor agonists (LABAs) have emerged from various companies. In particular, once …

Bronchodilators are central in the symptomatic management of asthma. It is likely that the
once-daily dosing of a bronchodilator would be a significant convenience and probably a …

To the Editors: b-blockers (inverse agonists) have an exactly opposite effect to b2-
adrenoceptor (b2-ADR) agonists and are currently contraindicated in asthma. This results …